ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and regulatory challenges [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, suggesting confidence in FDA approval despite known concerns from the FDA regarding clinical evidence [5]. - The defendants allegedly communicated misleading information to investors about the likelihood of NDA approval, leading to investor damages when the truth was revealed [5].